Giving you personalized support while on SYLVANT therapy

Your Patient Liaison (PL) is ready to connect with you on SYLVANT® (siltuximab) and idiopathic multicentric Castleman disease (iMCD)

Helga, Patient Liaison Helga, Patient Liaison

The PL Program* provides one-on-one support services at no additional cost to you by Recordati Rare Diseases. Program services may include

  • Providing education and answering questions about iMCD and SYLVANT
  • Helping you access your SYLVANT medication
  • Connecting you with other iMCD educational resources
*PL services are provided to help you manage your journey on SYLVANT therapy. Information provided by the PL Program is for educational purposes only and is not intended to replace the advice of your healthcare provider. PL Program services are available in Spanish.

To get started, complete
the Program Enrollment Opt‑In Form

COMPLETE THE OPT-IN FORM

Your PL can help you connect with
a variety of patient resources:

Access and reimbursement
support

  • Insurance verification—Confirming that your insurance company will cover SYLVANT, and help with understanding your insurance benefits
  • Insurance company education—Educating insurers about SYLVANT to help speed up decisions about coverage and payment

Financial assistance

  • Co-pay assistance program—Learn about your co-pay if you’re an eligible patient who receives SYLVANT infusions in an outpatient care setting
  • Patient Assistance Program (PAP)—Help you access SYLVANT if you’re an eligible patient who doesn’t have insurance or is underinsured
  • Additional referrals—Refer you to outside assistance sources if appropriate
See More

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information for SYLVANT for a complete list of ingredients.

Tell your healthcare provider if you have an infection. You should not receive SYLVANT if you have a severe infection.

Tell your healthcare provider if you have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT.

Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if SYLVANT will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT and for 3 months after stopping treatment.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if SYLVANT passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of SYLVANT include rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.

These are not all the possible side effects of SYLVANT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, please see the full Prescribing Information.